eli lilly mounjaro - Search News

News

Eli Lilly Stock Dives

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

The Motley Fool on MSN · 17h

Why Eli Lilly Stock Is Plunging Today

Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for the second quarter of 2025 that beat expectations, with soaring sales of type 2 diabetes drug Mounjaro and weight-loss drug Zepbound.

Barron's on MSN · 23h

Eli Lilly Stock Dives After Earnings Beat. Here’s Why.

Eli Lilly stock tumbled after it released the results for an experimental weight-loss pill study and reported a beat-and-raise quarter early Thursday. The medicine, Orforglipron, resulted in a weight reduction of on average 12.

Eli Lilly weight loss pill shows promise

CBS News on MSN · 11h

Eli Lilly weight loss pill shows promise in latest clinical trial, company says

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

Seeking Alpha · 12h

Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In

Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may simply want to hold for now.

TIME on MSN · 1d

Eli Lilly Says Its New Weight-Loss Pill Is Highly Effective

In eagerly awaited results from a new study, the pharmaceutical company Eli Lilly reports that a pill its scientists developed causes people who are overweight or obese, but not diabetic, to lose significant amounts of weight.

Eli Lilly Q2 Preview: Can Mounjaro and Zepbound Keep Delivering?

Eli Lilly & Co. reports Q2 2025 results before the U.S. market opens on August 7. Analysts expect revenue of approximately ...

18h

Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell, This Is A Buy The Dip Moment

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Pharmaceutical Technology on MSN18h

Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly

Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo ...

18h

Eli Lilly’s Mounjaro Shows Cardiovascular Benefits in Head-to-Head Trial

Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...

15h

Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

1don MSN

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

Eli Lilly hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company also released long-awaited ...

1don MSN

Wegovy, Mounjaro sales in India double on month in July

Sales of Danish drugmaker Novo Nordisk 's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month ...

Soap Central1d

"Crawling on the floor": Influencer Tana Mongeau details side effects of taking weight loss drug Mounjaro

Influencer Tana Mongeau has warned against taking the weight loss drug Mounjaro after she experienced severe side effects.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results